MedCity News June 17, 2024
We recently spoke with Nicole Bulochnik, senior vice president of drug strategy for Abarca, about what payers need to consider as demand for this group of weight-loss drugs remains high.
GLP-1s, like Ozempic and Wegovy, are creating a frenzy in healthcare. In just the last three months of 2022, providers wrote more than 9 million prescriptions for these drugs.
While GLP-1s have shown near-term weight-loss benefits, there are still many questions that remain about their long-term use – which is creating challenges for payers, providers and patients.
We recently spoke with Nicole Bulochnik, senior vice president of drug strategy for Abarca, about what payers need to consider as demand for these drugs remains high. The following interview has been edited...
Today's Sponsors
Today's Sponsor